将细胞疗法应用于B细胞急性淋巴细胞白血病二线治疗的前沿。
Moving cellular therapies to the front line for Ph B cell acute lymphoblastic leukemia.
作者信息
Feng Yanzhi, Leveille Etienne, Park Jae H, Müschen Markus
机构信息
Center of Molecular and Cellular Oncology, Yale University, New Haven, CT 06511, USA.
Cellular Therapy Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.
出版信息
Cell Rep Med. 2025 Jul 15;6(7):102184. doi: 10.1016/j.xcrm.2025.102184.
Chemotherapy-free regimens have gained increasing attention as frontline treatments for B cell acute lymphoblastic leukemia (B-ALL) due to the limitations of chemotherapy. Zhang and colleagues conducted the first trial incorporating CAR-T into Ph B-ALL frontline treatment, demonstrating remarkable efficacy and tolerability..
由于化疗存在局限性，无化疗方案作为B细胞急性淋巴细胞白血病（B-ALL）的一线治疗方法越来越受到关注。张及其同事开展了首个将嵌合抗原受体T细胞（CAR-T）纳入Ph B-ALL一线治疗的试验，显示出显著的疗效和耐受性。
Zotero 插件